A Phase 4 interventional study of Cefazolin and Vancomycin in Infection, Surgical Site, sponsored by Hamilton Health Sciences Corporation. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by Hamilton Health Sciences Corporation · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing vancomycin in Surgical Wound Infection — 4 open to participants now, 5 under way, 1 of them phase 3. Vancomycin · Surgical Wound Infection.
Among the 20 studies testing vancomycin in Surgical Wound Infection, this one has the largest planned enrollment, is one of 2 that started in 2026, is one of 9 in phase 4, and was the 18th registered.
747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.
Browse Surgical Wound Infection studies →4 of the 20 studies testing vancomycin in Surgical Wound Infection are open now, in 3 countries. Recruiting first, the newest first:
Major Extremity Trauma Research Consortium · Sites in United States
Ages 18–64
Assiut University · Sites in Egypt
Ages 1 days–18 yrs
University of Manitoba · Sites in Canada
Ages 18+
By country, each count listing its studies:
Vancomycin: first FDA approval 1964 (VANCOCIN HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →
Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 4 · Phase 4 9
First in 2009; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 38,000 is above the median of 200 across 583 interventional studies indexed under Surgical Wound Infection.
Median enrollment 329 across the 20 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 20 has an industry lead sponsor. The 10 most frequent:
Hamilton Health Sciences Corporation is the lead sponsor of 242 studies on the registry; 38 are open to participants now.
Hamilton Health Sciences Corporation has 4 studies filed under Surgical Wound Infection — fewer than ten, so there is no comparison to draw.
2 of the studies testing vancomycin in Surgical Wound Infection that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03839914The University of Hong KongEvaluating the Efficacy and Safety of Intra-wound Vancomycin Powder in High Risk Patients | 2027-03-31 |
| NCT07547826Assiut UniversityEfficacy and Cost-Effectiveness of Topical Vancomycin Powder in Preventing Pediatric Ventriculoperitoneal Shunt Infections Across Different Etiologies | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing vancomycin in Surgical Wound Infection, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this pragmatic, multi-centre factorial cluster randomized cross-over trial is to assess the efficacy of a combination of cefazolin plus vancomycin compared to cefazolin monotherapy, as well as a comparison of short versus long-term prophylaxis with four study arms: 1) cefazolin short-term, 2) cefazolin long-term, 3) cefazolin plus vancomycin short-term and 4) cefazolin plus vancomycin long-term.
Although antibiotic prophylaxis is considered the cornerstone of prevention for sternal surgical site infections (s-SSIs), the most effective antimicrobial regimen and optimal duration remain unclear. There is a pressing need to determine how best to prevent sternal surgical site infections and at the same time reduce adverse events from unnecessary antibiotic exposure. Currently, due to the lack of evidence, unproven approaches prevail and adherence to guidelines is poor. Rigorous randomized controlled trials data are needed for improved patient care.
A factorial cluster randomized cross-over trial, a design not used previously in this field, will address these gaps. To date, we have successfully enrolled close to 6,000 eligible patients in the vanguard study, and have shown that the trial as planned is feasible and operationally highly cost-effective.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult patients (≥18 years of age) undergoing open-heart surgery (i.e. sternotomy, including minimally-invasive surgical techniques through mini-sternotomies)
Exclusion Criteria:
Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery. The intraoperative dose at 4 hours after the first dose or upon wound closure (whatever comes first).
Drug: Cefazolin
Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery. The intraoperative dose at 4 hours after the first dose or upon wound closure (whatever comes first) and the five post-operative doses in the long-term arms will be 2g every 8 hours.
Drug: Cefazolin
Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery. The intraoperative dose at 4 hours after the first dose or upon wound closure (whatever comes first). Vancomycin will be dosed at roughly 15mg/kg body weight intravenously, i.e. 1g or 1.5g if greater than 85kg body weight and is to be administered within 60-90 minutes of the surgical procedure.
Drug: Cefazolin · Drug: Vancomycin
Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery. The intraoperative dose at 4 hours after the first dose or upon wound closure (whatever comes first) and the five post-operative doses in the long-term arms will be 2g every 8 hours. Vancomycin will be dosed at roughly 15mg/kg body weight intravenously, i.e. 1g or 1.5g if greater than 85kg body weight and is to be administered within 60-90 minutes of the surgical procedure. The same dose will be used for the 3 post-operative doses in the long-term arm.
Drug: Cefazolin · Drug: Vancomycin
administration as outlined
Also known as: Kefzol, Ancef
administered as outlined
Also known as: Vancocin, Firvanq
Deep incisional or organ/space (complex) sternal surgical site infection (CDC/NHSN)
Sternal surgical site infections are defined by clinical and microbiological criteria of infection at the surgical site that are associated with the operative procedure occurring within 90 days after surgery.
Time frame: 3 months post-surgery
All types of sternal surgical site infections (superficial, deep, organ; (CDC/NHSN)
Sternal surgical site infections are defined by clinical and microbiological criteria of infection at the surgical site that are associated with the operative procedure occurring within 90 days after surgery.
Time frame: 3 months post-surgery
Clostridium difficile infection
Laboratory confirmed
Time frame: 3 months post-surgery
Mortality
Mortality in participants with an active infection
Time frame: 3 months post-surgery
Number of patients with acute kidney injury
Acute kidney injury following the Acute Kidney Injury Network definition
Time frame: 7 days post surgery
Number of patients with sternal revision surgery
For suspected sternal surgical site infection
Time frame: 3 months post surgery
Rate of antimicrobial resistant organisms causing sternal wound infections
including relevant susceptibilities and stratified by study arm
Time frame: 3 months post-surgery
No study locations are listed for this record.
Start is estimated for Mar 2026; primary completion for Apr 2028, 25 months later.
Of 45 non-industry phase 4 interventional studies under Surgical Wound Infection, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's planned 25 months is below that.
Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 16 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vancomycin
Hamilton Health Sciences Corporation →